COVID-19感染与疫苗接种状态对头颈部鳞状细胞癌退伍军人结局的影响
该回顾性队列研究利用退伍军人事务部企业数据仓库,纳入14262例住院期间接受COVID-19检测的头颈部鳞状细胞癌退伍军人,其中4754例(33.3%)检测阳性。阳性患者60天死亡率及急性呼吸衰竭、急性呼吸窘迫综合征、肺炎发生率均高于阴性患者。阳性检测前2周至6个月接种疫苗者急性呼吸衰竭和肺炎发生率低于未接种者,但60天死亡无显著生存优势。
要点
- COVID-19阳性患者60天死亡率4.7% vs 阴性2.0%(p<0.001)。
- 阳性患者急性呼吸衰竭15.4% vs 7.1%,肺炎20.0% vs 6.4%(均p<0.001)。
- 阳性前2周至6个月接种疫苗者急性呼吸衰竭13.2% vs 未接种16.0%(p=0.034)。
核心结论
- COVID-19感染可能显著增加头颈部鳞状细胞癌患者的60天死亡率和呼吸系统并发症发生率。
- 感染前2周至6个月接种COVID-19疫苗可能降低呼吸系统并发症的严重程度,但本研究未显示显著的死亡获益。
- 这些数据强调需要对该脆弱人群进行呼吸道感染监测和疫苗接种。
研究设计与样本
- 回顾性队列研究,通过退伍军人事务部(VA)企业数据仓库纳入住院期间接受COVID-19检测且既往诊断为头颈部鳞状细胞癌的退伍军人。
- 根据国际疾病分类(ICD)编码构建口腔、口咽、下咽、喉及鼻咽头颈部鳞状细胞癌患者队列。
- 收集临床/人口学数据、疫苗接种状态及60天死亡率、60天心血管并发症和60天呼吸系统并发症发生率。
主要发现
- 14262例接受检测的患者中,4754例(33.3%)阳性,9508例(67.7%)阴性。
- 阳性患者较阴性患者60天死亡率升高(4.7% vs 2.0%,p<0.001)。
- 阳性患者较阴性患者急性呼吸衰竭发生率升高(15.4% vs 7.1%,p<0.001)。
- 阳性患者较阴性患者急性呼吸窘迫综合征发生率升高(0.9% vs 0.2%,p<0.001)。
- 阳性患者较阴性患者肺炎发生率升高(20.0% vs 6.4%,p<0.001)。
关键数值与推荐
- 阳性检测前2周至6个月接种疫苗组较未接种组急性呼吸衰竭发生率降低(13.2% vs 16.0%,p=0.034)。
- 阳性检测前2周至6个月接种疫苗组较未接种组肺炎发生率降低(16.7% vs 20.9%,p=0.003)。
- 对60天内死亡的患者进行逻辑回归,阳性检测前2周至6个月接种疫苗者无显著生存优势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of both COVID-19 infection and vaccination status on patients with head and neck squamous cell carcinoma (HNSCC) remains unknown. OBJECTIVE: To determine the impact of COVID-19 infection and vaccination status on 60-day mortality, cardiovascular, and respiratory complications in patients with a prior diagnosis of HNSCC. METHODS: This was a retrospective cohort study through the Veterans Affairs (VA) Corporate Data Warehouse of Veterans with HNSCC who were tested for COVID-19 during any inpatient VA medical center admission. A cohort of patients was created of Veterans with a diagnosis of HNSCC of the oral cavity,oropharynx, hypopharynx, larynx, and nasopharynx based on International Classification of Disease (ICD) codes. Data collected included clinical/demographic data, vaccination status, and incidence of 60-day mortality, 60-day cardiovascular complication (including myocardial infarction, venous thromboembolism, cerebrovascular accident), and 60-day respiratory complication (including acute respiratory failure, acute respiratory distress syndrome, and pneumonia). The interactions between COVID-19 infection, vaccination status, morbidity and mortality were investigated. RESULTS: Of the 14 262 patients with HNSCC who were tested for COVID-19 during inpatient admission, 4754 tested positive (33.3%), and 9508 (67.7%) tested negative. Patients who tested positive demonstrated increased 60-day mortality (4.7% vs. 2.0%, respectively; p < 0.001), acute respiratory failure (ARF; 15.4% vs. 7.1%, p < 0.001), acute respiratory distress syndrome (ARDS; 0.9% vs. 0.2%, p < 0.001), and pneumonia (PNA; 20.0% vs. 6.4%, p < 0.001) compared to those who never tested positive, respectively. Patients who received COVID-19 vaccination between 2 weeks and 6 months prior to a positive test demonstrated decreased rates of ARF (13.2% vs. 16.0%, p = 0.034) and PNA (16.7% vs. 20.9%, p = 0.003) compared to the unvaccinated group. A logistic regression of patients with COVID-19 infections who died within 60 days was performed, with no significant survival advantage among patients vaccinated between 2 weeks and 6 months prior to the positive test. CONCLUSION: COVID-19 infection may significantly increase rates of 60-day mortality and respiratory complications in patients with HNSCC. COVID-19 vaccination between 2 weeks and 6 months prior to infection may decrease severity of respiratory complications but did not show significant mortality benefits in this study. These data highlight the need for surveillance of respiratory infection and vaccination in this vulnerable population.
引用
- Johns JD, Choe EJ, Chisolm PF, et al. The impact of COVID-19 and vaccination status on outcomes in veterans with head and neck squamous cell carcinoma. Head Neck. 2024. PMID: 38433326. doi:10.1002/hed.27714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。